Login / Signup

A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients.

Michael B LillyChunli WuYu KeWen-Pin ChenAdam C SoloffKent ArmesonNoriko N YokoyamaXiaotian LiLiankun SongYing YuanChristine E McLarenXiaolin Zi
Published in: Clinical and translational medicine (2024)
The maximum tolerated dose was identified as 150 mg/day of lycopene in combination with docetaxel/ADT for the treatment of metastatic prostate cancer patients. Small increases in plasma exposure to docetaxel were observed with lycopene co-administration. Mechanistically significant effects were seen on angiogenesis and insulin-like growth factor 1 signalling by lycopene co-administration with docetaxel/ADT.
Keyphrases
  • locally advanced
  • prostate cancer
  • squamous cell carcinoma
  • small cell lung cancer
  • benign prostatic hyperplasia
  • replacement therapy
  • wound healing
  • growth hormone